{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:41Z","timestamp":1753891781926,"version":"3.41.2"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Research on myasthenia gravis (MG) has undergone rapid development in recent years. This article aimed to elucidate the characteristics of MG publications over the past 20\u2009years and analyze emerging trends using bibliometric methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Information on MG articles was obtained from the Web of Science Core Collection and stored in Excel for quantitative analyses. Bibliometric analyses were performed using CiteSpace and VOSviewer to visualize publications according to countries\/regions, institutions, journals, and authors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,610 publications were included in the analysis. The USA had the highest number of publications (NP) and H-index. Among the institutions, the University of Oxford had the highest NP, followed by the University of Toronto and Duke University. Close cooperation was observed among countries and institutions. The most productive author was Renato Mantegazza, followed by Jan J. Verschuuren, and Amelia Evoli. <jats:italic>Muscle &amp;amp; Nerve<\/jats:italic> published the most articles on MG, followed by the <jats:italic>Journal of Neuroimmunology<\/jats:italic> and <jats:italic>Neuromuscular Disorders<\/jats:italic>. The keyword with the highest strength is \u201cneuromuscular transmission,\u201d followed by \u201csafety\u201d and \u201crituximab.\u201d Co-citation analysis includes 103 publications cited at least 65 times, categorized into four clusters. Additionally, 123 keywords cited more than 40 times were analyzed and divided into five clusters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This bibliometric analysis shows the framework of research over the past 20\u2009years by mapping the scholarly contributions of various countries or regions, institutions, journals, and authors in MG. The analysis also explores future trends and prospective directions, emphasizing individualized treatment based on subtypes, novel immunotherapeutic approaches, and thymectomy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1320344","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T13:04:26Z","timestamp":1703768666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yukun","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiqi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anni","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxia","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.25068","article-title":"Epidemiology of myasthenia gravis in northern Portugal: frequency estimates and clinical epidemiological distribution of cases","volume":"54","author":"Santos","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","article-title":"A national epidemiological study of myasthenia gravis in Australia","volume":"19","author":"Gattellari","year":"2012","journal-title":"Eur J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3988\/jcn.2016.12.3.340","article-title":"Incidence and prevalence of myasthenia gravis in Korea: A population-based study using the National Health Insurance Claims Database","volume":"12","author":"Park","year":"2016","journal-title":"J Clin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/0165551507087238","article-title":"Bibliometrics to webometrics","volume":"34","author":"Thelwall","year":"2008","journal-title":"J Inf Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jns.2019.02.001","article-title":"Cognitive dysfunction in mice with passively induced MuSK antibody seropositive myasthenia gravis","volume":"399","author":"Sabre","year":"2019","journal-title":"J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s10072-021-05077-6","article-title":"Benefit and danger from immunotherapy in myasthenia gravis","volume":"42","author":"Rodolico","year":"2021","journal-title":"Neurol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1212\/NXI.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1257\/jel.40.2.483","article-title":"Who talks to whom? Intra-and interdisciplinary communication of economics journals","volume":"40","author":"Pieters","year":"2002","journal-title":"J Econ Lit"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor\u2013related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis\u2020","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis \u2014 autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: A 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteriod treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of Thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody\u2013positive myasthenia gravis: A multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/S0022-510X(09)70586-6","article-title":"FP59-FR-06 clinical and serological study of myasthenia gravis in a south Asian population using both radioimmunoprecipitation and cell-based assays","volume":"285","author":"Chang","year":"2009","journal-title":"J Neurol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-musk antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"Piddlesden","year":"1996","journal-title":"J Neuroimmunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1756286420904207","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"577424","DOI":"10.1016\/j.jneuroim.2020.577424","article-title":"Severe worsening of myasthenic symptoms after the eculizumab discontinuation","volume":"349","author":"Uzawa","year":"2020","journal-title":"J Neuroimmunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J Neurol"},{"key":"ref43","first-page":"4372","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume-title":"J Clin Invest","author":"Ulrichts","year":"2018"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","article-title":"Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia","volume":"32","author":"Caballero-\u00c1vila","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"102895","DOI":"10.1016\/j.jaut.2022.102895","article-title":"Poor responses and adverse outcomes of myasthenia gravis after thymectomy: predicting factors and immunological implications","volume":"132","author":"Chen","year":"2022","journal-title":"J Autoimmun"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s11845-018-1936-5","article-title":"Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago journal rank, source-normalised impact per paper, H-index, and alternative metrics","volume":"188","author":"Roldan-Valadez","year":"2019","journal-title":"Ir J Med Sci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1320344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T13:04:28Z","timestamp":1703768668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1320344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":52,"alternative-id":["10.3389\/fneur.2023.1320344"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1320344","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2023,12,28]]},"article-number":"1320344"}}